ASCO 2026: BeOne Medicines presented at this year's meeting long-term data on Brukinsa in CLL and combo data with the company's Bcl-2. Chairman & CEO John V. Oyler discusses that and new modalities

5 hours ago
1 min read

He highlights the importance of the long term Brukinsa data, which is the top selling BTK inhibitor today. Plus, we discuss degraders, antibody-drug conjugates, and bispecifics.

https://vimeo.com/1197191613

Recent Posts

See All

$ASCO 2026: Aulos Bioscience presented updated phase 2 data in checkpoint inhibitor-refractory metastatic melanoma for its IL-2 redirecting antibody, imneskibart$

ASCO 2026: Aulos Bioscience presented updated phase 2 data in checkpoint inhibitor-refractory metastatic melanoma for its IL-2 redirecting antibody, imneskibart

ASCO 2026: Allogene announced a CEO succession plan late last week. The two leaders behind it discuss why now is the right time, and update us on the progress of the company's programs

ASCO 2026: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-β with EGFR for its fusion protein in HPV negative head & neck

ASCO 2026: BeOne Medicines presented at this year's meeting long-term data on Brukinsa in CLL and combo data with the company's Bcl-2. Chairman & CEO John V. Oyler discusses that and new modalities

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight